Pfizer Goes Big On Generic Injectables With Acquisition Of 15 Products From India’s Claris
This article was originally published in PharmAsia News
Executive Summary
AHMEDABAD, India - Two months after Pfizer signed a comprehensive in-licensing agreement for more than 50 oral and injectable products with Aurobindo Pharma, the U.S. company has entered into another deal, with India's Claris Lifesciences, to commercialize 15 products covering a broad range of therapeutic areas including anti-infectives and pain drugs
You may also be interested in...
Off FDA’s Hook, India’s Claris Moves To Link Up Again With Pfizer, But Falters
Claris has been through grueling times implementing corrections mandated by U.S. FDA and set its sights on reclaiming a valuable supply deal, but Pfizer has distanced itself from the company.
Off FDA’s Hook, India’s Claris Moves To Link Up Again With Pfizer, But Falters
Claris has been through grueling times implementing corrections mandated by U.S. FDA and set its sights on reclaiming a valuable supply deal, but Pfizer has distanced itself from the company.
With Emerging Markets On Radar, AstraZeneca Close To Teaming Up With India's Intas For Sourcing Sterile And Oncology Drugs
MUMBAI - AstraZeneca is days away from signing an agreement with India's Intas Pharmaceuticals for supplies of a large number of generic sterile and oncology products to be sold in emerging markets. The deal will likely cover as many as 45 products to be sold in nine markets, with the scope for expanding the range of products further